AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

AMIKACIN SULFATE

7 registrations across 3 African markets— 6 active

Markets with AMIKACIN SULFATE

Recent registrations

Brand / ProductMarketHolderStatusExpires
AMIKACIN SULPHATE INJECTION (Each 2ml contains Amikacin Sulfate 500mg)🇬🇭GhanaactiveOct 2030
AMIKACIN SULPHATE INJECTION (Each 2ml contains Amikacin Sulfate 500mg)🇬🇭GhanaactiveOct 2030
MIKACIN 500MG/2ML INJECTION
INJECTION
🇲🇼MalawiexpiredApr 2004
AMIKACIN SULFATE
PARENTERAL ORDINARY VIALS
🇺🇬UgandaLABORATE PHARMACEUTICA LS INDIA LIMITEDactive
AMIKACIN SULFATE
PARENTERAL ORDINARY VIALS
🇺🇬UgandaLABORATE PHARMACEUTICA LS INDIA LIMITEDactive
AMIKACIN SULFATE
PARENTERAL ORDINARY VIALS
🇺🇬UgandaROYAL PHARMA 2011 LIMITEDactive
AMIKACIN SULFATE
PARENTERAL ORDINARY VIALS
🇺🇬UgandaROYAL PHARMA 2011 LIMITEDactive

AMIKACIN SULFATE in Africa — Regulatory Overview

AMIKACIN SULFATE is registered across 3 African markets with 7 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Uganda, Ghana, Malawi. AfricaRegulatory refreshes this data daily from official government sources.

Of the 7 registrations, 6 (86%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.